Fda approves regeneron drug for macular degeneration cbs. Regn announced positive twoyear results from the phase iii panorama study on lead drug eylea aflibercept injection 2 mg. Regeneron s eylea is a drug used to treat several eye diseases. Eylea has become a blockbuster for regeneron, and sales are still on the rise. Sign up for more eylea aflibercept injection information. American health assistance experts and people living with macular degeneration clarksburg, md the u. Can regeneron weather novartis eylea rival and praluent new. Regeneron s key drug, eylea, which is approved for various ophthalmology indications neovascular agerelated macular degeneration, diabetic macular edema and macular. Jan 03, 2018 eylea, which treats a leading cause of blindness in the elderly wet agerelated macular degeneration and related eye conditions, accounts for most of regenerons revenue. The recommended dosage of eylea in patients with dme is 2 milligrams mg every two months. Regeneron reports positive eylea data from latestage study. The great success of regeneron and the momentum seen over the past decade has been the outcome of the company obtaining approval for eylea back in 2011, giving the company a great blockbuster at hand.
Eylea is a vascular endothelial growth factor vegf inhibitor that treats neovascular wet agerelated macular degeneration amd, macular edema following retinal vein occlusion rvo, diabetic macular edema dme, and diabetic retinopathy dr. Eylea s revenues should continue to increase as it the. May 05, 2020 the company said there was limited impact from covid19 on sales of eylea, a treatment for wet, agerelated macular degeneration, in the first quarter, though sales were down in april. Regeneron stock is downgraded on competition from novartis.
Regenerons eylea has mysterious rise in side effect reports. The panorama trial showed that by one year 20% of untreated patients developed proliferative diabetic eye disease, and eylea reduced this risk by 85% to 88% when administered using an every 16week or eightweek dosing regimen, respectively, said george d. Eylea aflibercept for the treatment of wet amd clinical trials arena. Eylea is the third amd drug to be approved by the fda. Food and drug administration fda has approved eylea for the treatment of neovascular wet agerelated macular degeneration amd, macular. Regenerons eylea has mysterious rise in side effect. Could regeneron pharmaceuticals be a millionairemaker. Fda approves regeneron drug for macular degeneration cbs news. Increase in side effects over the past several months, an increased number of patients who receive eylea injections have experienced sharp declines in vision, pain, and even vision loss. Regn announced positive twoyear results from the phase iii panorama study on lead drug eylea aflibercept injection 2 mg at the angiogenesis, exudation, and.
Food and drug administration fda has approved a supplemental biologics license application sbla for eylea aflibercept injection in patients with wet agerelated macular degeneration wet amd. Food and drug administration fda has approved eylea aflibercept injection for the treatment of diabetic macular edema dme. The recommended dose for eylea is 2 mg every four weeks. Nov 18, 2011 eylea is the third amd drug to be approved by the fda. Eylea injection treatment of macular degeration amdf. Macugen inhibits a single form of vegf, while lucentis, like eylea, blocks all forms. Food and drug administration fda rejected the companys attempt to secure a supplemental approval for its blockbuster drug eylea as a onceper 12week treatment for wet agerelated macular degeneration wet amd. Feb 22, 2018 reported side effects raise concerns for regenerons eylea published. The recommended dose for eylea is 2 milligrams mg every 4 weeks monthly.
Regeneron stock is climbing after earnings beat expectations. Food and drug administration fda has approved eylea aflibercept injection for the treatment of macular edema following retinal vein occlusion rvo, which includes macular edema following branch retinal vein occlusion brvo in addition to the previouslyapproved. Why eylea is still regeneron pharmaceuticals most important drug despite competition, there are big demographic tailwinds supporting eyleas sale. Oct, 2016 regeneron is investing hundreds of millions of dollars into small cap ocular therapeutix as it looks to develop a new form of its blockbuster eye drug eylea aflibercept. Novartis takes on regeneron with amd drug that needs fewer. The company said there was limited impact from covid19 on sales of eylea, a treatment for wet, agerelated macular degeneration, in the first quarter, though sales were down in april.
Regeneron pharma hits twoyear high amid novartis woes. Eylea is intended to treat the chronic eye disease that gradually destroys sharp, central vision. Common and rare side effects for eylea intravitreal. Eylea aflibercept injection is a prescription medicine approved for the treatment of patients with. It is also used to treat swelling in the retina caused by a blockage in the blood vessels. Pictures 12 scary things your eyes say about your health. Fda approves regenerons eylea for diabetic retinopathy. Diabetic macular edema dme and diabetic retinopathy dr. The fda approved regeneron s new drug, eylea, an injection designed to treat the condition, on friday.
Call your doctor for medical advice about side effects. Eylea is also used to treat diabetic retinopathy, an eye disorder in diabetics that can lead to a buildup of fluid in the retina and cause blindness. Oct 26, 2018 the food and drug administration issued a complete response letter to regeneron pharmaceuticals over its prefilled syringe for the companys eye drug treatment eylea, the company disclosed thursday. Regenerons eylea stumbles as fda issues crl for new dosing.
After the drug is injected into the eye, a small number of people have a sharp decline in sight, experience. Reported side effects raise concerns for regenerons eylea. Dec 16, 2019 regeneron pharmaceuticals blockbuster maculardegeneration drug eylea may quickly lose market share to a new competitor from novartis, evercore isis josh schimmer warned. Fda approves macular degeneration drug eylea available for comment. Fda declines to approve prefilled syringe version of. Eylea aflibercept is a prescription medication for retinal diseases, which is injected into the eye. Eylea aflibercept injection is a vegf inhibitor formulated as an injection for the eye.
Apr 30, 2020 regenerons key drug, eylea, which is approved for various ophthalmology indications neovascular agerelated macular degeneration, diabetic macular edema and macular edema, among others. Aflibercept, sold under the brandname eylea and zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. Regeneron pharmaceuticals announced that the fda has approved its eylea injection treatment for wet agerelated macular degeneration amd. Regeneron pharmaceuticals is responsible for manufacturing eylea, which was approved by the fda in 2011. Momenta, mylan plan trial of biosimilar to regeneron eye drug. Jun 21, 2019 eylea is used to treat wet agerelated macular degeneration. It was developed by regeneron pharmaceuticals and is approved in the united states and europe. Fda approves macular degeneration drug eylea brightfocus. Fda hits regeneron with crl for eylea syringe biopharma dive. Please see the full prescribing information for eylea. Despite novartis beovu entry, eye drug eylea recorded its best performance since launch in terms of volume and sales in the fourth quarter, regeneron commercial chief marion mccourt said.
Eylea, an injectable drug that prevents blindness, grew by 14% in the u. Eylea aflibercept injection receives fda approval for the. Why eylea is still regeneron pharmaceuticals most important drug. Fda approves eylea aflibercept injection for diabetic retinopathy. Increased reports of intraocular inflammation due to eylea. Feb 22, 2018 by alex keown shares of regeneron pharmaceuticals, inc. Regeneron announces fda approval of eylea aflibercept. Food and drug administration fda has approved eylea aflibercept injection for the treatment of macular edema following central retinal vein occlusion crvo. The following information is not intended to endorse any particular medication. Regeneron pharmaceuticals topselling eye drug, eylea, bested roches lucentis and avastin in a u. Yancopoulos, md, phd, president and chief scientific officer at regeneron. Regenerons eylea approved for macular edema following crvo. Regeneron is investing hundreds of millions of dollars into small cap ocular therapeutix as it looks to develop a new form of its blockbuster eye drug eylea aflibercept.
The fda has approved regeneron pharmaceuticals aflibercept injection, eylea, for the treatment of all stages of diabetic retinopathy. It is an inhibitor of vascular endothelial growth factor vegf. Eylea aflibercept injection receives fda approval for. Regeneron provides regulatory update on eylea aflibercept. Regenerons eylea top choice for severe diabetesrelated. In the news release, regeneron announces fda approval of eylea aflibercept injection for the treatment of wet agerelated macular.
Eylea aflibercept injection is contraindicated in patients with ocular. Regeneron pharmaceuticals inc said on thursday the u. Regeneron submitted a supplemental biologics license application sbla to the fda for the use of eylea in central retinal vein occlusion crvo. May 23, 2019 our eylea aflibercept side effects drug center provides a comprehensive view of available drug information on the potential side effects when taking this medication. Regeneron reports positive eylea data from latestage. Regenerons eylea is a drug used to treat several eye diseases. Oct 04, 2012 in september, the food and drug administration approved regeneron pharmaceuticals eylea aflibercept injection for the treatment of macular edema following central retinal vein occlusion. Food and drug administration declined to approve a prefilled syringe version of its blockbuster eye drug eylea. Eylea aflibercept injection for the treatment of diabetic macular edema. Fda approves regeneron drug for macular degeneration. Food and drug administration fda on november 18 approved the new drug application for aflibercept ophthalmic solution trade name eylea, a new product for treatment of wet. Fda approves eylea aflibercept injection sbla in wet age. Regn is a leading science and technology company delivering lifetransforming medicines for serious diseases.
Eylea aflibercept injection approved for diabetic retinopathy. Eylea vial side effects by likelihood and severity common side effects. All three of these amd drugs are given by injection. Nov 21, 2011 fda approves regeneron drug for macular degeneration. Regenerons sbla for eylea accepted by fda, action date set. Feb 06, 2020 despite novartis beovu entry, eye drug eylea recorded its best performance since launch in terms of volume and sales in the fourth quarter, regeneron commercial chief marion mccourt said. Can regeneron weather novartis eylea rival and praluent.
564 983 884 1359 1328 100 7 1039 1109 551 660 62 72 675 190 320 480 1057 527 708 705 1434 673 1082 1117 1176 104 639 511 111 1347 517